他汀类药物使用与卵巢癌风险:来自全国性巢式病例对照研究中关于产次、绝经和子宫内膜异位症效应修饰的证据
基于丹麦和瑞典全国登记数据的巢式病例对照研究,纳入11,874例卵巢癌病例和474,960名对照,他汀使用与卵巢癌风险总体无关联(OR=0.96,95%CI 0.91-1.01),但在子宫内膜异位症女性(OR=0.70,95%CI 0.53-0.91)和无产次女性(OR=0.86,95%CI 0.79-0.93)中他汀使用与风险降低相关。
要点
- 他汀使用与卵巢癌风险总体无关联(OR=0.96,95%CI 0.91-1.01)。
- 子宫内膜异位症女性中他汀使用与卵巢癌风险降低相关(OR=0.70,95%CI 0.53-0.91)。
- 无产次女性中他汀使用与卵巢癌风险降低相关(OR=0.86,95%CI 0.79-0.93)。
核心结论
- 他汀使用与卵巢癌风险总体无关联,但在子宫内膜异位症和无产次女性中他汀使用与风险降低相关,提示他汀可能具有预防潜力。
研究设计与样本
- 基于丹麦和瑞典高质量登记数据的两个全国性巢式病例对照研究,纳入11,874例卵巢癌病例,按年龄个体匹配474,960名对照。
主要发现
- 他汀使用与卵巢癌风险总体无关联(OR=0.96;95%CI 0.91-1.01),与使用时长和强度亦无关联。
- 子宫内膜异位症女性中他汀使用与卵巢癌风险降低相关(OR=0.70;95%CI 0.53-0.91)。
- 无产次女性中他汀使用与卵巢癌风险降低相关(OR=0.86;95%CI 0.79-0.93)。
临床怎么用
- 作者认为,在子宫内膜异位症女性和无产次女性中,他汀使用与卵巢癌风险降低相关,提示他汀可能具有预防措施的潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous results on the association between statin use and risk of ovarian cancer (OC) are inconsistent, warranting further investigation. This study aims to examine the association between statin use and risk of OC in a large study population. METHODS: Based on two nationwide nested case-control studies utilizing data from Danish and Swedish high-quality registries, we identified 11,874 OC cases who were individually matched on age to 474,960 controls using risk-set sampling. Conditional logistic regression was performed separately on the country-specific data to calculate odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) for the association between statin use and risk of OC. Country-specific estimates were combined based on a fixed-effect assumption. Furthermore, we examined potential effect modifications by a priori selected OC risk factors on the association between statin use and OC risk. RESULTS: We found no overall association between statin use and risk of OC (OR = 0.96; 95 % CI: 0.91-1.01); neither with duration nor intensity of use. However, statin use was associated with a decreased risk of OC in subsets of women with endometriosis (OR = 0.70; 95 % CI: 0.53-0.91), and nulliparous women (OR = 0.86; 95 % CI: 0.79-0.93). CONCLUSION: We found an effect modification of some known ovarian cancer risk factors on the association between statin use and risk of OC. In women with endometriosis, and in nulliparous women, respectively, statin use was associated with a decreased risk of OC, suggesting statins may have potential as a preventive measure.
引用
- Bouazzi M, Zheng G, Wang J, et al. Use of statins and risk of ovarian cancer: evidence on effect modification by parity, menopause and endometriosis from nationwide nested case-control studies. Gynecol Oncol. 2025. PMID: 40499207. doi:10.1016/j.ygyno.2025.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。